Track PHIO and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Phio Pharmaceuticals Corp
411 Swedeland Road, King of Prussia, PA, United States, 19406
IPO
2012
Employees
6
Industry
Biotechnology
Sector
Healthcare
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20250+3
3
Q2 20250+5
5
2-quarter cumulative
0 sells8 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0